Aspen Pharmacare Holdings Ltd (APN) - Total Assets

Latest as of June 2025: ZAC135.89 Billion ZAC ≈ $72.22 Million USD

Based on the latest financial reports, Aspen Pharmacare Holdings Ltd (APN) holds total assets worth ZAC135.89 Billion ZAC (≈ $72.22 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Aspen Pharmacare Holdings Ltd shareholders equity for net asset value and shareholders' equity analysis.

Aspen Pharmacare Holdings Ltd - Total Assets Trend (2003–2025)

This chart illustrates how Aspen Pharmacare Holdings Ltd's total assets have evolved over time, based on quarterly financial data.

Aspen Pharmacare Holdings Ltd - Asset Composition Analysis

Current Asset Composition (June 2025)

Aspen Pharmacare Holdings Ltd's total assets of ZAC135.89 Billion consist of 28.5% current assets and 71.5% non-current assets.

Asset Category Amount (ZAC) % of Total Assets
Cash & Equivalents ZAC0.00 4.7%
Accounts Receivable ZAC13.34 Billion 9.8%
Inventory ZAC18.01 Billion 13.3%
Property, Plant & Equipment ZAC0.00 0.0%
Intangible Assets ZAC67.21 Billion 49.5%
Goodwill ZAC5.20 Billion 3.8%

Asset Composition Trend (2003–2025)

This chart illustrates how Aspen Pharmacare Holdings Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Aspen Pharmacare Holdings Ltd.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Aspen Pharmacare Holdings Ltd's current assets represent 28.5% of total assets in 2025, a decrease from 49.2% in 2003.
  • Cash Position: Cash and equivalents constituted 4.7% of total assets in 2025, down from 11.9% in 2003.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 52.0% of total assets, an increase from 29.0% in 2003.
  • Asset Diversification: The largest asset category is intangible assets at 49.5% of total assets.

Aspen Pharmacare Holdings Ltd Competitors by Total Assets

Key competitors of Aspen Pharmacare Holdings Ltd based on total assets are shown below.

Company Country Total Assets
Daihan Pharmaceutical Co.Ltd
KQ:023910
Korea ₩344.02 Billion
Aurobindo Pharma Limited
NSE:AUROPHARMA
India Rs525.46 Billion
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
China CN¥56.56 Billion
Ningbo Menovo Pharm Co Ltd
SHG:603538
China CN¥4.75 Billion
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
China CN¥7.26 Billion
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
China CN¥2.26 Billion
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
China CN¥1.69 Billion
Hainan Honz Pharmaceutical Co
SHE:300086
China CN¥1.88 Billion

Aspen Pharmacare Holdings Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.21 1.81 2.03
Quick Ratio 1.18 1.07 1.12
Cash Ratio 0.00 0.00 0.00
Working Capital ZAC21.21 Billion ZAC19.71 Billion ZAC18.66 Billion

Aspen Pharmacare Holdings Ltd - Advanced Valuation Insights

This section examines the relationship between Aspen Pharmacare Holdings Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 0.59
Latest Market Cap to Assets Ratio 0.02
Asset Growth Rate (YoY) -2.3%
Total Assets ZAC135.89 Billion
Market Capitalization $3.28 Billion USD

Valuation Analysis

Below Book Valuation: The market values Aspen Pharmacare Holdings Ltd's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Aspen Pharmacare Holdings Ltd's assets decreased by 2.3% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Aspen Pharmacare Holdings Ltd (2003–2025)

The table below shows the annual total assets of Aspen Pharmacare Holdings Ltd from 2003 to 2025.

Year Total Assets Change
2025-06-30 ZAC135.89 Billion
≈ $72.22 Million
-2.34%
2024-06-30 ZAC139.16 Billion
≈ $73.95 Million
+3.63%
2023-06-30 ZAC134.28 Billion
≈ $71.37 Million
+20.57%
2022-06-30 ZAC111.38 Billion
≈ $59.19 Million
+1.54%
2021-06-30 ZAC109.68 Billion
≈ $58.29 Million
-17.64%
2020-06-30 ZAC133.17 Billion
≈ $70.77 Million
+8.87%
2019-06-30 ZAC122.32 Billion
≈ $65.00 Million
-7.92%
2018-06-30 ZAC132.84 Billion
≈ $70.60 Million
+14.22%
2017-06-30 ZAC116.30 Billion
≈ $61.81 Million
+11.51%
2016-06-30 ZAC104.30 Billion
≈ $55.43 Million
+17.96%
2015-06-30 ZAC88.42 Billion
≈ $46.99 Million
+7.11%
2014-06-30 ZAC82.55 Billion
≈ $43.87 Million
+81.74%
2013-06-30 ZAC45.42 Billion
≈ $24.14 Million
+43.20%
2012-06-30 ZAC31.72 Billion
≈ $16.86 Million
+18.36%
2011-06-30 ZAC26.80 Billion
≈ $14.24 Million
+35.33%
2010-06-30 ZAC19.80 Billion
≈ $10.52 Million
+58.13%
2009-06-30 ZAC12.52 Billion
≈ $6.65 Million
+15.42%
2008-06-30 ZAC10.85 Billion
≈ $5.77 Million
+44.03%
2007-06-30 ZAC7.53 Billion
≈ $4.00 Million
+76.42%
2006-06-30 ZAC4.27 Billion
≈ $2.27 Million
+36.13%
2005-06-30 ZAC3.14 Billion
≈ $1.67 Million
+48.66%
2004-06-30 ZAC2.11 Billion
≈ $1.12 Million
+25.45%
2003-06-30 ZAC1.68 Billion
≈ $893.74K
--

About Aspen Pharmacare Holdings Ltd

JSE:APN South Africa Drug Manufacturers - Specialty & Generic
Market Cap
$3.28 Billion
ZAC6.17 Trillion ZAC
Market Cap Rank
#4673 Global
#33 in South Africa
Share Price
ZAC13900.00
Change (1 day)
-1.16%
52-Week Range
ZAC9100.00 - ZAC14268.00
All Time High
ZAC34515.40
About

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic ag… Read more